In an interview with SmartTRAK, Robert Levy, MD, president of the International Neuromodulation Society (INS), provides a preview of the research, emerging technologies, and trends in neuromodulation that will be at the INS 2019 14th World Congress to be held May 23-30, 2019 in Sydney, Australia. 

The meeting will highlight several important topics, including the use of neurostimulation to reduce opioid use, closed-loop neurostimulation, and advances in non-invasive brain stimulation, including for the treatment of post-traumatic stress disorder, depression, and for enhancing memory and learning.

In terms of research, Dr. Levy said Sam Eldabe, MD of the United Kingdom will provide a critical evaluation of clinical trials in neuromodulation. Researchers will also present the latest insight into mechanism of action, new data on neurostimulation for cardiac ischemia, as well as research on use of deep brain stimulation (DBS) for obesity, eating disorders and addiction. Researchers will also present important pivotal trial results, including: the Evoke Study (Saluda Medical), evaluating closed-loop spinal cord stimulation (SCS); the SURF study (Stimwave Technologies), comparing different wireless SCS frequencies and waveforms; and the ReActiv8 trial (Mainstay Medical), evaluating the use of a restorative neurostimulation system for nocioceptive chronic low back pain. 

On the technology front, the INS’s Innovation Day will highlight disruptive innovations in neuromodulation, and will feature panel discussions and presentations by researchers and major shareholders from early stage start-ups, middle-stage start-ups and well-established companies.

To find out more about the INS World Congress, click on the following video to listen to SmartTRAK’s interview with Dr. Levy recorded via phone from his office in Florida. A transcript of the interview is also provided below.

Arthrosurface hopes to expand the market for joint arthroplasty with a novel patellofemoral arthroplasty implant and five-year data demonstrating long-term clinical benefits for treating patients with patellofemoral pain earlier in the treatment continuum, with evidence suggesting that it halts the progression of osteoarthritis (OA).

Today, many of these patients fall into a treatment gap. As much as 22% of the US population could be suffering from patellofemoral pain, according to a recent analysis of data from 23 studies. PLoS One Many orthopedic surgeons remain unconvinced that surgical management is of long-term benefit. Instead they choose to manage these patients with conservative treatment until they become candidates for joint replacement.

To find out more about the Company’s new patellofemoral arthroplasty implant, the WaveKahuna, and how it can address surgeon concerns about long-term clinical benefits, SmartTRAK interviewed Arthrosurface CEO Steve Ek, and Gregory Nicholson, MD, Rush University Medical Center at the 2019 American Academy of Orthopaedic Surgeon’s (AAOS) Annual Meeting held March 12-16 in Las Vegas, NV.

Beautiful Gothenburg, Sweden is hosting EWMA 2019 - the European Wound Management Association conference, on June 5-9.

Gothenburg, Sweden's second largest city after Stockholm, located on the coast in southwestern Sweden, is considered "the quintessential 'second city': understatedly hip and unexpectedly vibrant with neoclassical architecture lining its tram-rattled streets, locals sunning themselves beside canals, and always an interesting cultural or social event going on."

Here are some of SmartTRAK's top things to do when taking a break from the conference. And we know what we're talking about - SmartTRAK's Senior Analyst, Advanced Wound Care, Lennart Stadler lives there!

IRVINE, CALIF. (PRWEB) MAY 13, 2019

BioMedGPS is excited to host its subscribers and guests on Tuesday, June 4th, at a very special Pre-EWMA 2019 event at Gothenburg’s Universeum Aquarium.

SmartTRAK’s Advanced Wound Care Experts will serve as panelists. Susan Paquette - SmartTRAK VP & General Manager, Wound - will be providing overall insights on the wound market and Lennart Stadler - SmartTRAK Senior Analyst, Advanced Wound Care - will be presenting data on important trends and innovations.

Med device giants are scooping up innovative technologies

The Spine market is bustling with activity so far this spring, with two notable acquisitions hot off the press.

Medtronic announced its acquisition of Titan Spine,  strengthening Medtronic's interbody position with Titan Spine's portfolio, which consists of a full line of titanium, surface-enhanced interbody fusion devices featuring Titan’s nanoLock surface technology. The acquisition is expected to close during Medtronic's first fiscal quarter ending July 26, 2019, although terms of the deal were not disclosed. Titan Spine currently markets its line of Endoskeleton interbody devices in the US, Europe and Australia. This acquisition further validates the shift in the interbody market from PEEK to porous titanium. Medtronic already offers interbodies manufactured from Ti-coated PEEK (Pure Titanium Coating or PTC) and just last year launched a titanium 3D printed platform – TiONIC Technology - that enables more complex designs and integrated surface technologies for spine surgery implants.

SmartTRAK, the leading source of competitive intelligence used by the top ten global orthopedic & wound care companies, was cited as a source in 3M's presentation "3M to Acquire Acelity Inc." published on May 2.

#SAWC2019 in San Antonio is fantastic! So many things to do and see. Stay tuned for articles from SmartTRAK with updates and highlights. In the meantime, a few photos!

SmartTRAK talks with Raoul Verheggen, Global Product Director for DSM Biomedical, regarding the Company’s recent foray into the wound care space and how its addressing unmet needs for patients and businesses

Novel materials and components are key to innovative wound care products that provide superior patient outcomes. DSM Biomedical is a B2B supplier whose business it is to provide these unique components to the medical device industry. SmartTRAK talks with Raoul Verheggen of DSM Biomedical, Global Product Director for Wound, about the company, their capabilities and plans moving forward in support of wound care. A transcript of the interview is below. To listen to the interview recorded via Uberconference, click on the following video. 

SmartTRAK highlights key takeaways from the recent North American Neuromodulation (NANS) 22nd annual meeting held in Las Vegas in January, including important company news, trials, technologies, and trends affecting the US market for spinal cord stimulation (SCS) and what's next in this market. This informative article also includes exclusive interviews with leading figures in Neuromodulation including Saluda Medical CEO John Parker, President Abbott Neuromodulation Keith Boetigger, Medtronic Senior VP and Pain Therapies President Marshall Stanton, and Medtronic Senior Global Product Manager for Pain Stimulation and Early Interventions Brian Ranck ...

Sequential improvement despite tough comps, supply disruption and pricing pressure